DuPont de Nemours Inc. (DD)

Soft demand in specific markets and the sluggishness in China and Europe pose headwinds for the Zacks Chemicals Diversified industry. DD, ALB and KRO are poised to navigate the industry challenges.

DuPont's Costa Rica expansion introduces sterile healthcare packaging, a first for the region's medical device industry.

Innovation, cost savings and healthcare acquisitions support DD as it navigates weak demand and hefty separation costs in 2025.

Dow tackles weak demand with cost cuts and cash actions, while DuPont gains from acquisitions in healthcare and innovation.

DD hits 100% renewable electricity for EU operations, marking a major step toward its 2050 net-zero emissions goal using RECs and solar installations.

DD launches AmberChrom TQ1 resin, boosting oligonucleotide and peptide purification with high capacity, purity, and scalability.

The market has recovered most of its losses from last month's correction, and many quality stocks appear expensive again, prompting some investors to wait for another correction. DuPont de Nemours, In...

NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of DuPont de Nemours, Inc. ("DuPont" or the "Company") (NYSE:DD). Such investors are a...

DuPont de Nemours Inc. DD posted better-than-expected first-quarter 2025 results on Friday.

DuPont de Nemours reported solid Q1 earnings with a 4.6% YoY sales growth, driven by higher volumes in China and AI expansion in Electronics. Despite potential tariff headwinds, DuPont's forward P/E o...